UChicago Medicine completes construction phase of new cancer facility

FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test

Astellas doses first patient in Phase 3 lung cancer study

X-Chem and Relay Therapeutics collaborate on Phase 3 milestone

BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis

AbbVie and Iambic agree collaboration for discovery and development of small molecule therapies

Grunenthal to acquire Stivarga cancer treatment

Precigen announces FDA platform technology designation for AdenoVerse

Enhertu recommended for EU approval in early HER2-positive breast cancer

PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS

Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts

Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase

Jubilant Therapeutics reports preliminary clinical data from Phase 1/2 study in myeloproliferative neoplasms at SOHO 2026

GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma

Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer